This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abboud, N.
Right arrow Articles by Casadevall, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abboud, N.
Right arrow Articles by Casadevall, A.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, July 2008, p. 1115-1123, Vol. 15, No. 7
1071-412X/08/$08.00+0     doi:10.1128/CVI.00015-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Immunogenicity of Bacillus anthracis Protective Antigen Domains and Efficacy of Elicited Antibody Responses Depend on Host Genetic Background{triangledown}

Nareen Abboud1 and Arturo Casadevall1,2*

Department of Microbiology and Immunology,1 Department of Medicine, Division of Infectious Diseases, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 104612

Received 9 January 2008/ Returned for modification 19 February 2008/ Accepted 1 May 2008

Neutralizing antibodies to Bacillus anthracis protective antigen (PA), a component of anthrax toxin, mediate protection against anthrax. PA is antigenically complex and can elicit protective and nonprotective antibodies. Furthermore, vaccinated individuals demonstrate considerable variability in their antibody responses to PA. To explore the relationship between PA structure and antigenicity, we produced Escherichia coli strains expressing full-length PA (PA1-4), domains 2 to 4 (PA2-4), domain 1, (PA1), and domain 4 (PA4) and evaluated the immunogenicities and protective efficacies of the protein fractions in four mouse strains (strains A/J, BALB/c, C57BL/6, and Swiss Webster). Immunization with PA1-4 resulted in significantly higher lethal toxin-neutralizing antibody titers than immunization with any recombinant protein (rPA) fraction of PA. The magnitude and neutralizing capacity of the antibody response to full-length PA and its fragments varied depending on the mouse strain. We found no correlation between the antibody titer and the neutralizing antibody titer for A/J and Swiss Webster mice. In C57BL/6 mice, antibody titers and neutralization capacity correlated for two of four rPA domain proteins tested, while BALB/c mice displayed a similar correlation with only one rPA. By correlating the reactivity of immune sera with solvent-exposed linear peptide segments of PA, we tentatively assign the presence of four new linear B-cell epitopes in PA amino acids 121 to 150, 143 to 158, 339 to 359, and 421 to 440. We conclude that the genetic background of the host determines the relative efficacy of the antitoxin response. The results suggest that the variability observed in vaccination studies with PA-derived vaccines is a result of host heterogeneity and implies a need to develop other antigens as vaccine candidates.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: (718) 430-3730. Fax: (718) 430-8968. E-mail: casadeva{at}aecom.yu.edu

{triangledown} Published ahead of print on 14 May 2008.

Clinical and Vaccine Immunology, July 2008, p. 1115-1123, Vol. 15, No. 7
1071-412X/08/$08.00+0     doi:10.1128/CVI.00015-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kelly-Cirino, C. D., Mantis, N. J. (2009). Neutralizing Monoclonal Antibodies Directed against Defined Linear Epitopes on Domain 4 of Anthrax Protective Antigen. Infect. Immun. 77: 4859-4867 [Abstract] [Full Text]  
  • Thomas, J. M., Moen, S. T., Gnade, B. T., Vargas-Inchaustegui, D. A., Foltz, S. M., Suarez, G., Heidner, H. W., Konig, R., Chopra, A. K., Peterson, J. W. (2009). Recombinant Sindbis Virus Vectors Designed To Express Protective Antigen of Bacillus anthracis Protect Animals from Anthrax and Display Synergy with Ciprofloxacin. CVI 16: 1696-1699 [Abstract] [Full Text]  
  • Abboud, N., De Jesus, M., Nakouzi, A., Cordero, R. J. B., Pujato, M., Fiser, A., Rivera, J., Casadevall, A. (2009). Identification of Linear Epitopes in Bacillus anthracis Protective Antigen Bound by Neutralizing Antibodies. J. Biol. Chem. 284: 25077-25086 [Abstract] [Full Text]  
  • Oscherwitz, J., Yu, F., Jacobs, J. L., Liu, T.-H., Johnson, P. R., Cease, K. B. (2009). Synthetic Peptide Vaccine Targeting a Cryptic Neutralizing Epitope in Domain 2 of Bacillus anthracis Protective Antigen. Infect. Immun. 77: 3380-3388 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»